CVS Health Corporation $CVS is Rhenman & Partners Asset Management AB’s 7th Largest Position

Rhenman & Partners Asset Management AB lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 21.0% in the fourth quarter, Holdings Channel reports. The firm owned 335,500 shares of the pharmacy operator’s stock after purchasing an additional 58,138 shares during the period. CVS Health makes up about 2.5% of Rhenman & Partners Asset Management AB’s investment portfolio, making the stock its 7th biggest position. Rhenman & Partners Asset Management AB’s holdings in CVS Health were worth $26,625,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of CVS. Alteri Wealth LLC grew its holdings in CVS Health by 3.2% during the third quarter. Alteri Wealth LLC now owns 4,195 shares of the pharmacy operator’s stock worth $316,000 after acquiring an additional 131 shares during the period. TOWER TRUST & INVESTMENT Co grew its holdings in CVS Health by 0.8% during the fourth quarter. TOWER TRUST & INVESTMENT Co now owns 15,708 shares of the pharmacy operator’s stock worth $1,247,000 after acquiring an additional 132 shares during the period. Holistic Financial Partners grew its holdings in CVS Health by 4.1% during the third quarter. Holistic Financial Partners now owns 3,397 shares of the pharmacy operator’s stock worth $256,000 after acquiring an additional 133 shares during the period. CYBER HORNET ETFs LLC grew its holdings in CVS Health by 4.1% during the third quarter. CYBER HORNET ETFs LLC now owns 3,442 shares of the pharmacy operator’s stock worth $259,000 after acquiring an additional 134 shares during the period. Finally, LS Investment Advisors LLC grew its holdings in CVS Health by 3.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,575 shares of the pharmacy operator’s stock worth $284,000 after acquiring an additional 135 shares during the period. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the firm’s stock in a transaction dated Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the sale, the executive vice president directly owned 10,133 shares in the company, valued at approximately $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the sale, the director owned 4,824,799 shares of the company’s stock, valued at $450,877,466.55. The trade was a 7.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,441,551 shares of company stock valued at $323,703,977 over the last 90 days. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CVS. Royal Bank Of Canada lifted their target price on CVS Health from $93.00 to $107.00 and gave the stock an “outperform” rating in a report on Thursday, May 7th. Truist Financial lifted their target price on CVS Health from $102.00 to $108.00 and gave the stock a “buy” rating in a report on Monday, June 1st. Leerink Partners reaffirmed an “outperform” rating and set a $98.00 target price on shares of CVS Health in a report on Thursday, March 5th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CVS Health in a report on Thursday. Finally, Wells Fargo & Company lifted their target price on CVS Health from $102.00 to $103.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. Twenty-two investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $100.68.

CVS Health Trading Up 1.4%

Shares of CVS opened at $101.87 on Friday. The business’s 50-day moving average price is $86.91 and its 200 day moving average price is $80.78. The stock has a market capitalization of $129.98 billion, a P/E ratio of 44.88, a P/E/G ratio of 0.98 and a beta of 0.62. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $102.77. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. The firm had revenue of $100.43 billion for the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue was up 6.2% on a year-over-year basis. During the same quarter last year, the business posted $2.25 EPS. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Analysts expect that CVS Health Corporation will post 7.44 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Investors of record on Thursday, April 23rd were paid a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.6%. CVS Health’s dividend payout ratio (DPR) is currently 117.18%.

CVS Health News Summary

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS is expanding access to GLP-1 weight-loss drugs, including bringing back Zepbound and loosening restrictions on newer oral therapies, which could improve customer engagement and prescription volume while supporting its broader healthcare platform. Is CVS (CVS) Using GLP-1 Access and AI Tools to Redefine Its Healthcare Moat?
• Positive Sentiment: The company is also pushing AI deeper into pharmacy, insurance, and care delivery operations, aiming to cut administrative burden, improve efficiency, and potentially widen margins over time. Healthy Returns: CVS Health executives on reducing health care’s biggest pain points
• Positive Sentiment: CVS Health has launched Aetna Mental Health on Demand, which gives members faster access to care and shows the company is trying to strengthen service offerings across its insurance business. 5 Low Price-to-Book Stocks That Are Worth Buying in June
• Positive Sentiment: Recent coverage notes CVS at a 52-week high and highlights strong post-earnings momentum, while screening screens and “trending stock” mentions suggest investor interest remains elevated. CVS Health Corporation (CVS) Hit a 52 Week High, Can the Run Continue?
• Neutral Sentiment: CVS is also working with Fluency to move autonomous AI agents from pilot projects into production, but the financial impact is still early and not yet quantified. CVS is Using Fluency to Close Enterprise AI Deployment Gap
• Neutral Sentiment: News that Mass General Brigham and CVS are moving closer to a primary care partnership and that the stock is being heavily discussed by retail investors adds attention, but these items are not immediate earnings drivers. Mass General Brigham and CVS primary care partnership moves closer to reality
• Negative Sentiment: Musab Balbale’s departure adds some leadership turnover, though the market may view it as a limited issue unless more executive changes follow. Musab Balbale Departs CVS Health

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.